title: Neoadjuvant therapy for marginally resectable (clinical N2), non-small cell lung cancer. American College of Radiology. ACR Appropriateness Criteria.
authors.affiliation: Medical College of Wisconsin, Milwaukee, USA.
authors.forename: R W
authors.initials: RW
authors.lastname: Byhardt
authors.forename: W T
authors.initials: WT
authors.lastname: Sause
authors.forename: W J
authors.initials: WJ
authors.lastname: Curran
authors.forename: D
authors.initials: D
authors.lastname: Fuller
authors.forename: M V
authors.initials: MV
authors.lastname: Graham
authors.forename: B
authors.initials: B
authors.lastname: Ko
authors.forename: R
authors.initials: R
authors.lastname: Komaki
authors.forename: T H
authors.initials: TH
authors.lastname: Weisenburger
authors.forename: L R
authors.initials: LR
authors.lastname: Kaiser
authors.forename: S A
authors.initials: SA
authors.lastname: Leibel
authors.forename: N C
authors.initials: NC
authors.lastname: Choi
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011013:Pneumonectomy; D015996:Survival Rate